DataMeds AI plans ChemoFx marketing relaunch, targets gynecologic cancer diagnostic rollout
MEDS•DataMeds AI plans to cut corporate management roles and redirect spending toward commercializing ChemoFx, a diagnostic for gynecologic cancers. The company is preparing a marketing relaunch and pursuing broader payer coverage, clinical analyses and research collaborations.
1. Commercialization plans
DataMeds AI said it will cut corporate management roles to redirect spending toward commercializing ChemoFx, which helps oncologists select chemotherapy regimens. The company is preparing a marketing relaunch targeting oncologists.
2. Coverage and research
ChemoFx was included for the first time in a Humana Medicaid coverage policy for gynecologic cancers, and DataMeds AI said it will position the diagnostic for broader payer uptake. The company is preparing clinical-utility analyses for peer review to support expansion into other solid tumors and pursuing research collaborations using a 70,000-sample tumor repository.
